With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.
Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 bill
Novartis' cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE.
Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumo
In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a sim